{
"@context": "https://schema.org",
"@type": "Article",
"headline": "FDA CBD Hearing Leaves Questions Unanswered",
"url": "https://www.lexblog.com/2019/06/04/fda-cbd-hearing-leaves-questions-unanswered/",
"identifier": {
"@type": "PropertyValue",
"name": "LexBlog Library record",
"value": "LEX-WK-78PWV01G",
"url": "https://www.lexblog.com/lib/78PWV01G/"
},
"datePublished": "2019-06-04T09:19:59-04:00",
"dateModified": "2019-06-04T13:32:55-04:00",
"author": {
"@type": "Person",
"name": "Snehal Trivedi"
},
"sourceOrganization": {
"@type": "Organization",
"name": "Foley Hoag LLP"
},
"organizationScope": "at-publication",
"isPartOf": "Cannabis & the Law",
"about": "Cannabis",
"sourceUrl": "http://www.cannabisandthelaw.com/2019/06/04/fda-cbd-hearing-leaves-questions-unanswered/",
"sourceStability": "may-move"
}